CD8A and neoplasm: Enhanced efficacy was reflected by improved tumor-specific immunity (figure 6C), increased T cell infiltration into tumors (figure 6D) and increased activation of splenic CD8+ T cells (figure 6E) demonstrating VVΔTKΔN1L-mIl12 as a powerful monotherapeutic agent that can mediate long-term control of tumors by augmentation of adaptive antitumor immune responses.